---
layout: post
title: "Patient-Focused Drug Development for Stimulant Use Disorder; Public Meeting; Request for Comments"
date: 2026-02-05 19:08:36 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-03159
original_published: 2020-02-18 00:00:00 +0000
significance: 8.00
---

# Patient-Focused Drug Development for Stimulant Use Disorder; Public Meeting; Request for Comments

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** February 18, 2020 00:00 UTC
**Document Number:** 2020-03159

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Patient-Focused Drug Development for Stimulant Use Disorder." The purpose of the public meeting is to allow FDA to obtain stakeholder perspectives on the impact of stimulant use disorder and views on treatment approaches for stimulant use disorder.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/02/18/2020-03159/patient-focused-drug-development-for-stimulant-use-disorder-public-meeting-request-for-comments)
- API: https://www.federalregister.gov/api/v1/documents/2020-03159

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
